While drug development continues to diversify, current obesity treatments are challenged by high rates of therapy discontinuation, weight regain, and lean mass loss, underscoring the limitations of available options. Moreover, obesity often presents with multiple comorbidities such as metabolic dysfunction-associated steatohepatitis (MASH) and cardiovascular diseases, highlighting the need for personalized treatment strategies.

Preclinical evidence indicates that GLP-1-based agents combined with therapies acting through distinct mechanisms, such as blocking activin type II receptors (Bimagrumab) or thyroid hormone receptor-β agonism (MGL-3196), can not only reduce body weight but also attenuate muscle loss, improve energy expenditure, and enhance dosing convenience. 

Join us as we explore how this approach offers a promising pathway to address long-term treatment needs and expand development. 

During this webinar, you will: 

• Understand the clinical evolution and expanding indications of GLP-1 therapies

• Review preclinical evidence for novel GLP-1 combinations (e.g., with Bimagrumab or MGL-3196)

• Explore key mouse models for obesity and its comorbidities, including MASH and cardiovascular disease

• Examine a case study using mouse models to evaluate GLP-1-receptor-targeted therapies

Date: Tuesday, November 18, 2025

Time: 8:00 AM PST | 10:00 AM CST | 11:00 AM EST | 5:00 PM CET

Duration: One Hour